Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKi) represent the treatment of choice for EGFR-mutated NSCLC, but the occurrence of resistance has sharply limited their efficacy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.